Locus Cell Co., Ltd. (TPEX:6891)
Taiwan · Delayed Price · Currency is TWD 50.70
+1.95 (4.00%)
Apr 17, 2026, 1:59 PM CST
Locus Cell Revenue
In the year 2025, Locus Cell had annual revenue of 12.74M TWD with 440.66% growth. Locus Cell had revenue of 3.45M in the half year ending June 30, 2025.
Revenue
12.74M
Revenue Growth
+440.66%
P/S Ratio
802.51
Revenue / Employee
240.34K
Employees
53
Market Cap
10.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.74M | 10.38M | 440.66% |
| Dec 31, 2024 | 2.36M | 1.95M | 480.30% |
| Dec 31, 2023 | 406.00K | -194.00K | -32.33% |
| Dec 31, 2022 | 600.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Adimmune | 1.40B |
| Ever Supreme Bio Technology | 1.02B |
| EirGenix | 1.01B |
| PharmaEngine | 911.42M |
| Medigen Vaccine Biologics | 613.17M |
| TaiMed Biologics | 611.35M |
| Tanvex BioPharma | 400.97M |
| TaiGen Biopharmaceuticals Holdings | 259.47M |